Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/118721
DC FieldValueLanguage
dc.contributorDepartment of Health Technology and Informatics-
dc.creatorGui, L-
dc.creatorLin, J-
dc.creatorYin, X-
dc.creatorZhao, J-
dc.creatorWang, K-
dc.creatorLiu, J-
dc.creatorWang, S-
dc.creatorCao, M-
dc.creatorLiu, X-
dc.creatorLin, L-
dc.creatorZheng, J-
dc.creatorZhong, Q-
dc.creatorYuan, Z-
dc.date.accessioned2026-05-14T03:06:54Z-
dc.date.available2026-05-14T03:06:54Z-
dc.identifier.issn1616-301X-
dc.identifier.urihttp://hdl.handle.net/10397/118721-
dc.language.isoenen_US
dc.publisherWiley-VCHen_US
dc.subjectBoron difluoride-based photosensitizeren_US
dc.subjectEndoplasmic reticulum stressen_US
dc.subjectHeavy-atom-freeen_US
dc.subjectImmunogenic cell deathen_US
dc.titleNear-infrared boron difluoride-based photosensitizers targeting endoplasmic reticulum stress for antitumor immunotherapyen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume36-
dc.identifier.issue34-
dc.identifier.doi10.1002/adfm.202519328-
dcterms.abstractEndoplasmic reticulum (ER) stress has attracted growing attention in recent years as a potential therapeutic target for cancer treatment. Photosensitizers serve as inducers of ER stress, exerting their effects through the generation of reactive oxygen species (ROS), which can enhance immunogenic cell death (ICD). However, photodynamic therapy (PDT) is constrained by tumor hypoxia and the short half-life of ROS, which hinders the therapeutic efficacy of photosensitizers. Herein, three ER-targeting, heavy-atom-free boron difluoride-based photosensitizers capable of generating Type I ROS are successfully synthesized. Among these compounds, BFE-3 exhibits the highest electron affinity and demonstrates superior Type I ROS generation efficiency. Notably, BFE-3 is found to effectively induce ER stress and initiate the mitochondrial apoptotic cascade pathway. More importantly, BFE-3 can promote the release of damage-associated molecular patterns (DAMPs) from tumor cells under light irradiation, which efficiently induce ICD and activate antitumor immune responses. This boron difluoride-based photosensitizer, as a heavy-atom-free system, provides insights for developing Type I ROS-generating photosensitizers, while also offering a potential strategy for ER stress-mediated antitumor immunotherapy.-
dcterms.accessRightsembargoed accessen_US
dcterms.bibliographicCitationAdvanced functional materials, 27 Apr. 2026, v. 36, no. 34, e19328-
dcterms.isPartOfAdvanced functional materials-
dcterms.issued2026-04-27-
dc.identifier.scopus2-s2.0-105027699313-
dc.identifier.eissn1616-3028-
dc.identifier.artne19328-
dc.description.validate202605 bcjz-
dc.description.oaNot applicableen_US
dc.identifier.SubFormIDG001676/2026-02en_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextThe authors are grateful to the National Key R&D Program of China (2023YFE0197700), the Excellent Young Foundation of Jiangsu Province (BK20250203), the Natural Science Fund for colleges and universities in Jiangsu Province (25KJB350009), the Taizhou Science and Technology Support Program (Social Development) Directive Project (TSL202512), the Fundamental Research Funds of Taizhou University (TZXYQD2024A030), the Fundamental Research Funds for the Central Universities (2632024TD02), the Joint Program on Health Science & Technology Innovation of Hainan Province (WSJK2025ZD209), the Key Science and Technology Plan Project of Lhasa (LSKJ202419), the Natural Science Foundation of China (32301154), and the Open Project of Key Laboratory of Reproductive Health Diseases Research and Translation of Ministry of Education (HNSZLAB202407).en_US
dc.description.pubStatusPublisheden_US
dc.date.embargo2027-04-27en_US
dc.description.oaCategoryGreen (AAM)en_US
Appears in Collections:Journal/Magazine Article
Open Access Information
Status embargoed access
Embargo End Date 2027-04-27
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.